Greenwich LifeSciences, Inc.
GLSI
$8.41
$0.415.13%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
12/3/2025
-
Tickeron - Stocks
12/3/2025
-
GuruFocus
12/3/2025
-
The Fly
12/3/2025
-
GuruFocus
12/3/2025
-
Globe Newswire
12/2/2025
-
Tickeron - Stocks
12/2/2025
-
Tickeron - Stocks
12/1/2025
-
Ticker Report
11/29/2025
-
MarketBeat
11/29/2025
-
Tickeron - Technical Analysis
11/29/2025
-
Tickeron - Technical Analysis
11/27/2025
-
Tickeron - Technical Analysis
11/27/2025
-
Tickeron - Technical Analysis
11/27/2025
-
Tickeron - Technical Analysis
11/26/2025
-
Tickeron - Stocks
11/25/2025
-
Tickeron - Stocks
11/20/2025
-
Tickeron - Stocks
11/19/2025
-
Tickeron - Stocks
11/19/2025
-
Tickeron - Stocks
11/18/2025
-
Tickeron - Stocks
11/17/2025
-
MarketBeat
11/15/2025
-
Zolmax
11/15/2025
-
Ticker Report
11/14/2025
-
Tickeron - Stocks
11/14/2025
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, November 14, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Apr 13 and 17 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
832 819 3232
Address
Building 14
Stafford, TX 77477
Stafford, TX 77477
Country
Year Founded
Business Description
Sector
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and...
more